Trial Profile
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer: A Randomized Controlled Clinical Trial
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Aug 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Irinotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 06 Sep 2018 New trial record